You are here:   Videos
Register   |  Login

Get Adobe Flash player Install latest flash player if this video gallery doesn't work.
Phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced NSCLC
From ASCO 2011 – A discussion with Geoffrey Shapiro, MD and PhD at the Dana-Farber Cancer Institute, Boston MA, on the open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Recent Video
| 
Most Viewed
Tumor Type : Search :